{"organizations": [], "uuid": "86b321ef284d303a3fb08145315d21640a78f92e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pulmatrix-announces-first-subject/brief-pulmatrix-announces-first-subject-dosed-in-phase-1-clinical-trial-of-pulmazole-idUSASB0C583", "country": "US", "domain_rank": 408, "title": "BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T17:13:00.000+02:00", "replies_count": 0, "uuid": "86b321ef284d303a3fb08145315d21640a78f92e"}, "author": "", "url": "https://www.reuters.com/article/brief-pulmatrix-announces-first-subject/brief-pulmatrix-announces-first-subject-dosed-in-phase-1-clinical-trial-of-pulmazole-idUSASB0C583", "ord_in_thread": 0, "title": "BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "pulmatrix inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 13 PM / in 14 minutes BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Pulmatrix Inc: \n* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSEâ„¢ FORMULATION OF ITRACONAZOLE \n* PHASE 1 DATA FOR CLINICAL TRIAL OF PULMAZOLE IS EXPECTED IN MID-2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-12T17:13:00.000+02:00", "crawled": "2018-02-12T17:36:12.001+02:00", "highlightTitle": ""}